Pancreatic Cancer Research

ResearcherIstituto Oncologico VenetoActive in the last 2 years

Sara Lonardi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7593-8138; OpenAlex author ID A5033536678, A5051613962, A5074404050. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
121
Papers, trials and grants by year

2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: 6 papers · 2024: 2 papers · 2025: 2 papers · 2026: 5 papers

Papers 22

  1. Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results f… Co-author DOI 10.1016/j.eclinm.2026.104190↗
  2. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … Co-author DOI 10.1016/s0140-6736(25)01685-x↗
  3. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Last author DOI 10.1093/oncolo/oyag085↗
  4. Conversion surgery vs. standard of care in pancreaTic cancer oligometastatic to the liver (SONAR: Surgery in Oligometastatic paNcreatic cAnceR) a randomized co… Co-author DOI 10.1186/s12885-025-15183-9↗
  5. Chemotherapy for Locally Advanced Pancreatic Cancer: The Dilemma of David Versus Goliath After NEOPAN. Co-author DOI 10.1200/jco-25-01517↗
  6. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  7. Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, It… Co-author DOI 10.1016/j.esmogo.2025.100217↗
  8. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Co-author DOI 10.1002/cam4.7345↗
  9. A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants. Co-author DOI 10.1016/j.pan.2024.09.006↗
  10. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1002/cam4.6111↗
  11. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Co-author DOI 10.1016/j.ejca.2023.04.012↗
  12. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  13. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. Co-author DOI 10.1016/j.modpat.2023.100251↗
  14. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  15. Role of Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Could It Be Considered a Predictor of Prognosis? Co-author DOI 10.3390/curroncol30060417↗
  16. Impact of Microscopic Confirmation on Therapeutic Management of Pancreatic Cancer Patients: Lessons from an Italian Regional Tumor Registry. Co-author DOI 10.3390/cancers14215372↗
  17. An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer. Last author DOI 10.3390/curroncol29020049↗
  18. Could Total Neoadjuvant Therapy Followed by Surgical Resection Be the New Standard of Care in Pancreatic Cancer? A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/jcm11030812↗
  19. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE … Co-author DOI 10.1016/j.annonc.2021.01.070↗
  20. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gem… First author DOI 10.1200/jco.20.02232↗
  21. Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0395↗
  22. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing… Co-author DOI 10.1186/s12885-020-07110-x↗

Closest collaborators

The 25 strongest of 121 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Letizia Procaccio · 11 shared papers, 2022–2026 · strength 2.34
  2. Francesca Bergamo · 9 shared papers, 2022–2026 · strength 1.82
  3. Michèle Milella · 7 shared papers, 2023–2026 · strength 1.12
  4. Mario Scartozzi · 6 shared papers, 2023–2026 · strength 1.00
  5. Michele Reni · 6 shared papers, 2021–2026 · strength 1.00
  6. Mariacristina Di Marco · 5 shared papers, 2023–2026 · strength 0.92
  7. Marina Macchini · 5 shared papers, 2023–2026 · strength 0.90
  8. Giulia Orsi · 5 shared papers, 2023–2026 · strength 0.90
  9. Ilario Giovanni Rapposelli · 5 shared papers, 2023–2026 · strength 0.84
  10. Elisa Giommoni · 5 shared papers, 2023–2026 · strength 0.76
  11. Guido Giordano · 5 shared papers, 2023–2026 · strength 0.76
  12. Giampaolo Tortora · 4 shared papers, 2023–2026 · strength 0.63
  13. Enrico Vasile · 4 shared papers, 2023–2026 · strength 0.63
  14. Federico Nichetti · 2 shared papers, 2026 · strength 0.63
  15. Monica Niger · 4 shared papers, 2023–2026 · strength 0.62
  16. Catia Carconi · 3 shared papers, 2024–2026 · strength 0.61
  17. Davide Melisi · 4 shared papers, 2020–2026 · strength 0.58
  18. Giuseppe Malleo · 3 shared papers, 2023–2026 · strength 0.56
  19. Andrea Pretta · 3 shared papers, 2023–2026 · strength 0.55
  20. Silvia Bozzarelli · 3 shared papers, 2023–2026 · strength 0.50
  21. Teresa Mercade Macarulla · 3 shared papers, 2021–2025 · strength 0.49
  22. Ferdinando De Vita · 3 shared papers, 2023–2026 · strength 0.48
  23. Alberto Zaniboni · 3 shared papers, 2023–2026 · strength 0.48
  24. Andrea Spallanzani · 3 shared papers, 2023–2025 · strength 0.46
  25. Ingrid Garajová · 3 shared papers, 2023–2025 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.